Table 1.
Demographic and clinical characteristics of the study population
| UC | CD | ||||||
| Clinical remission (n = 29) | Clinical activity (n = 22) | P | Clinical remission (n = 23) | Clinical activity (n = 27) | P | ||
| Male, n (%) | 10 (35) | 13 (59) | 0.096 | Male, n (%) | 14 (61) | 13 (48) | 0.407 |
| Age, yr, median (IQR) | 45 (35–55) | 43 (30–59) | 0.849 | Age, yr, median (IQR) | 40 (34–46) | 36 (26–49) | 0.386 |
| Disease duration, yr, median (IQR) | 9 (5–14) | 5 (0–15) | 0.083 | Disease duration, yr, median (IQR) | 11 (5–17) | 5 (1–7) | 0.011 |
| Age at diagnosis, yr, median (IQR) | 32 (25–39) | 31 (23–50) | 0.879 | Age at diagnosis, yr, median (IQR) | 29 (24–36) | 28 (20–42) | 0.845 |
| Previous surgical resection, n (%) | 0 | 1 (5) | 0.431 | Previous surgical resection, n (%) | 10 (44) | 6 (22) | 0.136 |
| Montreal extent,a n (%) | Montreal location,b n (%) | ||||||
| E1 | 4 (14) | 0 | L1 | 15 (65) | 15 (56) | ||
| E2 | 17 (59) | 5 (23) | 0.001 | L2 | 1 (4) | 1 (4) | |
| E3 | 8 (28) | 17 (77) | L3 | 7 (30) | 10 (37) | 0.211 | |
| L4 | 0 | 1 (4) | |||||
| Montreal behavior,c n (%) | |||||||
| B1 | 12 (52) | 7 (26) | |||||
| B2 | 3 (13) | 9 (33) | |||||
| B3 | 8 (35) | 11 (41) | 0.105 | ||||
| p | 8 (35) | 9 (33) | >0.999 | ||||
| Medication | Medication | ||||||
| 5-ASA, n (%) | 25 (86) | 12 (55) | 0.025 | 5-ASA, n (%) | 7 (30) | 1 (4) | 0.017 |
| Thiopurine, n (%) | 9 (31) | 6 (27) | >0.999 | Thiopurine, n (%) | 15 (65) | 10 (37) | 0.088 |
| Methotrexate, n (%) | 0 | 0 | — | Methotrexate, n (%) | 2 (9) | 2 (7) | >0.999 |
| Biological treatment, n (%) | 12 (41) | 7 (32) | 0.566 | Biological treatment, n (%) | 12 (52) | 14 (52) | >0.999 |
CD, Crohn's disease; IQR, interquartile range; UC, ulcerative colitis.
a
E1—proctitis; E2—left sided colitis; E3—pancolitis.
b
L1—ileal; L2—colonic; L3—ileocolonic; L4—upper disease.
c
B1—non-stricturing, non-penetrating; B2—stricturing; B3—penetrating; p—perianal disease.
5-ASA, 5-aminosalicylic acid.